Nalbuphine prodrug and pharmaceutical composition thereof

By using diacylglycerol, phosphatidylcholine, oxygen-containing organic solvents and organic acids in the long-acting sustained release formulation of nalbuphine, the problem of insufficient stability and analgesic effects in the prior art is solved, and the problem of achieving the The effect of high stability and continuous analgesic is suitable for clinical use.

CN118903132APending Publication Date: 2024-11-08SUZHOU NHWA PHARM RES CO LTD

Patent Information

Application Number
CN202410553088.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is still room for improvement in the stability and analgesic effects of existing nalbuphine long-acting sustained release formulations, especially in terms of stability and persistent analgesia to meet clinical needs.

Method used

Using a pharmaceutical composition containing diacylglycerol, phosphatidylcholine, oxygen-containing organic solvents and organic acids, the stability and analgesic effect of nalbuphine prodrugs are improved through specific ratios and storage methods, including the use of Components such as glyceryl dioleate, soybean phosphatidylcholine, N-methylacetamide and methanesulfonic acid form a stable pharmaceutical composition, and the effective mixing and release of drugs is achieved through devices such as dual-chamber pre-filled syringes.

Benefits of technology

It achieves high stability and rapid onset of the pharmaceutical composition, and is released slowly in the later stage, provides continuous analgesic effects, meets the clinical needs of long-term analgesics, and improves the compatibility and convenience of use of drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a novel long-acting analgesic nalbuphine prodrug, a pharmaceutical composition of the nalbuphine prodrug, and a preparation method of the pharmaceutical composition. According to the pharmaceutical composition provided by the invention, the compound as shown in the general formula I is combined with specific auxiliary materials, so that the obtained pharmaceutical composition is better in stability and less in impurity degradation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a nalbuphine prodrug and a pharmaceutical composition thereof, a preparation method thereof and an application thereof in the pharmaceutical industry. Background Art

[0002] Nalbuphine is a semisynthetic agonist-antagonist analgesic of the morphinan class. It is structurally similar to the opioid receptor antagonist naloxone and the potent opioid analgesic oxymorphone. It mainly exerts its pharmacological effects by stimulating κ receptors and antagonizing μ receptors. Its analgesic potency is similar to that of morphine, but it has fewer side effects and higher safety. It is mainly used in the treatment of moderate to severe pain. Nalbuphine takes effect within 2 to 3 minutes after intravenous administration, and takes effect within 15 minutes after intramuscular or subcutaneous injection. The onset plasma concentration is 12 μg / L, and the peak plasma concentration reaches 48 μg / L in 30 minutes. The half-life is about 5 hours. Depending on individual differences, the analgesic time is about 3 to 6 hours (see Beaver, WT, Feise, GA and Robb, D. (1981) Analgesic Effect of Intramuscular and Oral Nalbuphine in Postoperative Pain. Clinical Pharmacology and Therapeutics, 29, 174-180.). Therefore, for patients with severe or persistent pain, frequent injections or administration of nalbuphine are required.

[0003] Dinalbuphine sebacate (DNS), also known as senabuphine, is a dimer of nalbuphine. Its chemical structure is shown below:

[0004]

[0005] Senabuphine is a prodrug of nalbuphine formed by two nalbuphine molecules connected to a sebacyl group through an ester bond. It has no analgesic activity itself. After entering the blood, it is hydrolyzed into the active ingredient nalbuphine to exert an analgesic effect. Senabuphine is more lipid-soluble than nalbuphine and can be dissolved in the excipients of long-acting sustained-release preparations to be prepared into long-acting preparations. However, nalbuphine has better hydrophilicity and lower solubility in the excipients of long-acting preparations, making it unsuitable for the preparation of long-acting preparations. Currently, the long-acting sustained-release preparation of senabuphine is on the market and is used to relieve moderate to severe pain after surgery. It has the characteristics of strong and long-acting analgesia.

[0006] Patent WO2023020608 discloses an improved preparation of senabuphine, which comprises acylglycerol, phosphatidylcholine, at least one oxygen-containing organic solvent, at least one acid and senabuphine. The obtained pharmaceutical composition has higher stability, faster onset, longer duration of action, and can reduce injection pain and hemolysis. However, there is still a need to develop a nalbuphine prodrug with better stability and long-term analgesia and its pharmaceutical composition to meet clinical use needs. Summary of the invention

[0007] In order to solve the problems existing in the prior art, the present invention provides a new long-acting analgesic nalbuphine prodrug compound and a pharmaceutical composition comprising these compounds, and in particular provides a pharmaceutical composition of a nalbuphine prodrug with better stability.

[0008] Pharmaceutical composition

[0009] First, the present invention provides a pharmaceutical composition comprising a compound of general formula I, wherein the pharmaceutical composition comprises (a) diacylglycerol, (b) phosphatidylcholine, (c) an oxygen-containing organic solvent, (d) at least one organic acid and (e) the compound of general formula I;

[0010] Wherein, the nalbuphine prodrug compound has the following structure:

[0011]

[0012] Where n1 is 1 or 2;

[0013] When n1 is 1, R 1 is selected from: a straight chain or branched chain alkyl group containing 1 to 14 carbon atoms, an alkylene carboxyl group containing 1 to 15 carbon atoms, or H;

[0014] When n1 is 2, R 1 Selected from: -(CH 2 ) n2 -, where n2 is 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14 or 15.

[0015] The straight-chain or branched alkyl group containing 1 to 14 carbon atoms is preferably C 1~3 A straight or branched alkyl group, C 4~9 A straight or branched alkyl group, C 10~14 A straight chain or branched alkyl group;

[0016] The alkylene carboxyl group containing 1 to 15 carbon atoms is preferably a straight chain or branched chain alkylene carboxyl group containing 1 to 15 carbon atoms. Preferably, the alkylene carboxyl group containing 1 to 15 carbon atoms is selected from: -(CH2) n3-COOH, wherein n3 is an integer from 1 to 15.

[0017] In another preferred embodiment of the present invention, the compound represented by the general formula I, wherein R 1 Selected from methyl, ethyl, n-propyl, tert-butyl, n-hexyl, or -(CH2) 13 -CH 3 , n1 is selected from 1.

[0018] In another preferred embodiment of the present invention, the compound represented by the general formula I, wherein R 1 Selected from -(CH 2 ) n3 -COOH, n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, preferably n3 is 4, 6, 8, 10 or 12; n1 is 1.

[0019] In another preferred embodiment of the present invention, the compound represented by the general formula I, wherein R 1 Selected from -(CH2) n2 -, where n2 is 4, 6, 10, 12, 13, 14 or 15, and where n1 is 2.

[0020] In another preferred embodiment of the present invention, the pharmaceutical composition comprising a nalbuphine prodrug compound, wherein the nalbuphine prodrug compound is selected from the compounds shown in Table A below.

[0021] Table A: Exemplary Nalbuphine Prodrug Compounds

[0022]

[0023]

[0024] In a preferred embodiment, the pharmaceutical composition of the present invention, wherein in method A, the (a) diacylglycerol, (b) phosphatidylcholine and part of (c) oxygen-containing organic solvent are the first component of the pharmaceutical composition, and the remaining (c) oxygen-containing organic solvent, (d) at least one organic acid and (e) the compound represented by general formula I are the second component of the pharmaceutical composition; or in method B, (a) diacylglycerol, (b) phosphatidylcholine, (c) oxygen-containing organic solvent and (d) at least one acid are the first component of the pharmaceutical composition, and (e) the compound represented by general formula I is the second component of the pharmaceutical composition, and the first component and the second component are stored separately;

[0025] Further preferably, in method A, the weight ratio of the oxygen-containing organic solvent in the first component to that in the second component is (0.2-2):1, such as 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.8:1, 1:1, 1.5:1 or 2:1.

[0026] In a preferred embodiment, in the pharmaceutical composition of the present invention, the acyl group of (a) diacylglycerol is selected from lauroyl (C12:0), myristoyl (C14:0), palmitoyl (C16:0), phytanoyl (C16:0), palmitoleoyl (C16:1), stearoyl (C18:0), oleoyl (C18:1), elaidoyl (C18:1), linoleoyl (C18:2), linolenoyl (C18:3), arachidonic acid (C20:4), behenoyl (C22:0) and tetracosanoyl (C24:9), preferably oleoyl.

[0027] In one embodiment of the present invention, the acyl group is based on natural fatty acids, including but not limited to lauric acid, myristic acid, palmitic acid, phytanic acid, palmityl acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, arachidonic acid, behenic acid or lignoceric acid. The preferred source of the acyl group is palmitic acid, stearic acid, oleic acid and linolenic acid, particularly, preferably oleic acid.

[0028] In one embodiment of the present invention, the diacylglycerols comprise at least 50 wt% of glyceryl dioleate (GDO), preferably at least 80 wt% of GDO, more preferably substantially all of the diacylglycerols are GDO.

[0029] Typically, GDO and other diacylglycerols are present in a certain proportion of "impurity" esters with other chain lengths, etc. Thus, in one aspect, GDO as used herein is used to refer to any commercial grade of GDO (i.e., commercial purity GDO) containing accompanying impurities. These impurities can be separated and removed by purification, but such purification is rarely necessary if the grade is consistent. However, if necessary, "GDO" can be substantially chemically pure GDO, such as GDO that is at least 80% pure, preferably at least 85% pure, and more preferably at least 90% pure.

[0030] In one embodiment of the present invention, the (b) phosphatidylcholine (abbreviation, PC) may be derived from a natural source. Suitable sources of phosphatidylcholine include egg, heart (e.g., bovine), brain, liver (e.g., bovine) and plant sources including soybeans. Such sources may provide one or more components of (b) phosphatidylcholine, which may contain any mixture of phospholipids. Any single PC or mixture of PC from these or other sources may be used, but a mixture containing soybean PC or egg PC is very suitable, whereby the phosphatidylcholine of the present invention is selected from at least one of egg PC, heart PC, brain PC, liver PC, egg yolk PC or soybean PC, preferably at least one of egg PC, egg yolk PC or soybean PC, more preferably soybean PC.

[0031] In a preferred embodiment, a particularly advantageous combination of (a) diacylglycerols and (b) phosphatidylcholine is GDO and PC, in particular GDO and soy PC.

[0032] In one embodiment of the present invention, the content of diacylglycerol (a) is 40-65% by weight, for example, 40-45% by weight, 40-50% by weight, 40-55% by weight, 40-60% by weight, 40-65% by weight, 45-50% by weight, 45-55% by weight, 45-60% by weight, 45-65% by weight, 50-55% by weight, 50-60% by weight, 50-65% by weight, 55-60% by weight, 55-65% by weight, 60-65% by weight, etc., and all ranges included therein; further by way of example, the content of diacylglycerol (a) is 40-65% by weight, for example, 40-50% by weight, 40-55% by weight, 40-60% by weight, 40-65% by weight, 45-50% by weight, 45-55% by weight, 45-60% by weight, 45-65% by weight, 50-55% by weight, 50-60% by weight, 50-65% by weight, 55-60% by weight, 55-65% by weight, 60-65% by weight, etc., and all ranges included therein; The acylglycerols may be present in the pharmaceutical composition in an amount of about 40 wt%, about 41 wt%, about 44 wt%, about 45 wt%, about 46 wt%, about 47 wt%, about 48 wt%, 49 wt%, about 50 wt%, 51 wt%, 52 wt%, 53 wt%, 54 wt%, 55 wt%, 56 wt%, 57 wt%, 58 wt%, 59 wt%, 60 wt% or about 61 wt%, and the like, and ranges between any two values ​​thereof; preferably, the content of (a) diacylglycerols is 50-60 wt%, more preferably 54-58 wt%.

[0033] The content of the (b) phosphatidylcholine is 4-15% by weight, for example, 4-10% by weight, 10-15% by weight, 4-6% by weight, 4-8% by weight, 4-9% by weight, 5-6% by weight, 5-7% by weight, 5-8% by weight, 5-9% by weight, 5-10% by weight, 5-15% by weight, or 8-15% by weight, etc., and all ranges included therein; further by way of example, the (b) phosphatidylcholine may be present in the pharmaceutical composition in the following amounts: about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, about 15% by weight, and ranges between any two of the values; preferably, the content of the (b) phosphatidylcholine is 4-10% by weight, more preferably 5-8% by weight.

[0034] The first component includes an oxygen-containing organic solvent, which is beneficial for reducing the viscosity of the composition; the inclusion of an oxygen-containing organic solvent in the second component is beneficial for fully mixing the active ingredient compound represented by general formula I with the acid, thereby increasing the storage stability of the compound represented by general formula I. In one embodiment, (c) the oxygen-containing organic solvent is selected from amides, C 1-3 The amide is selected from at least one of N-methylpyrrolidone (NMP), dimethylformamide, 2-pyrrolidone and dimethylacetamide (DMAC, also known as N,N-dimethylacetamide); the C 1-3 The alcohol is selected from methanol, ethanol, isopropanol or propanol. The inventors have found through research that the stability of the compound represented by general formula I in NMP and DMAC is better than other oxygen-containing organic solvents, and preferably (c) the oxygen-containing organic solvent is N-methylpyrrolidone and / or dimethylacetamide.

[0035] In the pharmaceutical composition, the total amount of the oxygen-containing organic solvent is: 15-50% by weight, for example, 15-45% by weight, 30-45% by weight, 40-45% by weight, 15-40% by weight, 16-40% by weight, 20-40% by weight, 25-40% by weight, 30-40% by weight, 35-40% by weight, 15-35% by weight, 15-34% by weight, 20-35% by weight, 25-35% by weight, 30-35% by weight, 15-30% by weight, 20-30% by weight, 25-30% by weight, 15-25% by weight, 20-25% by weight, 15-20% by weight, 15-35% by weight, etc., and all ranges included therein; as an example, the component (c) contains The total amount of oxygen-containing organic solvent is, for example, about 15 wt%, about 20 wt%, about 25 wt%, about 26 wt%, about 27 wt%, about 28 wt%, about 29 wt%, about 30 wt%, about 31 wt%, about 32 wt%, about 33 wt%, about 34 wt%, about 35 wt%, about 36 wt%, about 37 wt%, about 38 wt%, about 39 wt%, about 40 wt% and the range between any two values; preferably 20-35 wt%; wherein the ratio of the content of oxygen-containing organic solvent in the first component to that in the second component in method A is (0.2-2):1, such as 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.8:1, 1:1, 1.5:1 or 2:1. It is further preferred that in method A, relative to the total weight of (a), (b), (c), (d) and (e), the content of the oxygen-containing organic solvent in the first component is 5-15 weight %, such as about 5 weight %, about 6 weight %, about 7 weight %, about 8 weight %, about 9 weight %, about 10 weight %, about 11 weight %, about 12 weight %, about 13 weight %, about 14 weight % or about 15 weight %, and the content of the oxygen-containing organic solvent in the second component is 10-30 weight %, such as about 10 weight %, about 15 weight %, about 16 weight %, about 17 weight %, about 18 weight %, about 19 weight %, about 20 weight %, about 21 weight %, about 22 weight %, about 23 weight %, about 24 weight % or about 25 weight %, etc.

[0036] In a specific embodiment, in the above-mentioned pharmaceutical composition, the content of the compound represented by the general formula I is 5 to 20% by weight, for example: 7 to 15% by weight, 10 to 15% by weight, 7.5 to 15% by weight, 7.5 to 12.5% ​​by weight, 7.5 to 10% by weight, 8 to 10% by weight, 8 to 11% by weight, 9 to 11% by weight, 9 to 10% by weight, 15 to 18% by weight, 15 to 20% by weight, about 7.5% by weight, about 7.9% by weight, about 8% by weight, about 8.2% by weight , about 9.2 weight %, about 9.5 weight %, about 10 weight %, about 10.5 weight %, about 10.6 weight %, about 11 weight %, about 11.5 weight %, about 12 weight %, about 14 weight %, about 15 weight %, about 16 weight %, about 17 weight %, about 18 weight %, about 19 weight %, about 20 weight % and the range between any two values, preferably the content of the compound represented by general formula I is 7 to 15 weight %, more preferably 8 to 12 weight %, and further preferably 9 to 11 weight %.

[0037] In a specific embodiment, the acid (d) is at least one of methanesulfonic acid, maleic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, and citric acid. The addition of acid is beneficial to improving the storage stability of the compound represented by the general formula I. The increase in stability can be demonstrated by the following: when the pharmaceutical composition contains the acid described in the present invention (especially methanesulfonic acid), its chemical stability is significantly improved, which is reflected in less impurity degradation; the same increase in stability is also reflected in increased physical stability, specifically, the addition of acid (especially methanesulfonic acid) can significantly reduce the crystallization problem of the compound represented by the general formula I in the pharmaceutical composition. Therefore, it is preferred that (d) includes methanesulfonic acid. The molar ratio of the compound represented by the general formula I to methanesulfonic acid is 0.9 to 3:1, which is advantageous. In particular, in the compound represented by the general formula I, when n1 is 1, the molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1, preferably 1.8 to 2.2:1, for example 2:1; when n1 is 2, the molar ratio of the compound represented by the general formula I to the organic acid is 0.9 to 1.2:1, preferably 1 to 1.2:1, especially 1:1. The content of maleic acid is 0 to 0.2% by weight, for example 0 to 0.02% by weight, 0 to 0.01% by weight, etc.

[0038] In a preferred embodiment, the pharmaceutical composition, wherein the content of the compound represented by the general formula I is 5 to 20% by weight, preferably 7 to 15% by weight;

[0039] The content of diacylglycerol is 40 to 65% by weight, preferably 50 to 60% by weight;

[0040] The content of phosphatidylcholine is 4 to 15% by weight, preferably 4 to 10% by weight;

[0041] The molar ratio of the compound represented by the general formula I to the organic acid is 0.9 to 3:1;

[0042] The content of the oxygen-containing organic solvent is 15 to 50% by weight, preferably 20 to 35% by weight;

[0043] The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e).

[0044] In a preferred embodiment, the pharmaceutical composition, wherein, when n1 is 1, the molar ratio of the compound represented by general formula I to the organic acid is 1.2-2.2:1; when n1 is 2, the molar ratio of the compound represented by general formula I to the organic acid is 0.9-1.2:1.

[0045] In a preferred embodiment, the pharmaceutical composition, wherein the content of the compound represented by the general formula I is 5 to 10% by weight; preferably, the compound represented by the general formula I is nalbuphine butyrate;

[0046] The content of diacylglycerol is 50-60% by weight;

[0047] The content of phosphatidylcholine is 4 to 10% by weight;

[0048] The content of the oxygen-containing organic solvent is 20 to 35% by weight;

[0049] When n1 is 1, the molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1;

[0050] When n1 is 2, the molar ratio of the compound represented by the general formula I to the organic acid is 0.9-1.2:1.

[0051] The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e).

[0052] In a preferred embodiment, in the pharmaceutical composition of the present invention, the compound represented by general formula I is nalbuphine butyrate, nalbuphine sebacate monoester or nalbuphine adipate diester.

[0053] In a preferred embodiment, the pharmaceutical composition, wherein (a) the diacylglycerol is diolein;

[0054] (b) the phosphatidylcholine is selected from at least one of egg PC, heart PC, brain PC, liver PC, egg yolk PC or soybean PC, preferably at least one of egg PC, egg yolk PC or soybean PC, more preferably soybean PC;

[0055] (c) the oxygen-containing organic solvent is selected from amides, C 1 -C 3The amides are selected from at least one of N-methylpyrrolidone, dimethylformamide, 2-pyrrolidone and dimethylacetamide, preferably N-methylpyrrolidone and / or dimethylacetamide.

[0056] (d) The organic acid is at least one of methanesulfonic acid, maleic acid, p-toluenesulfonic acid, acetic acid, fumaric acid and citric acid, preferably at least one of methanesulfonic acid or maleic acid.

[0057] In a preferred embodiment, the pharmaceutical composition of the present invention, wherein the diacylglycerol is selected from diolein; the phosphatidylcholine is selected from soybean phosphatidylcholine; the oxygen-containing organic solvent is selected from DMAC and / or NMP; the organic acid is selected from methanesulfonic acid, and optionally further comprises maleic acid.

[0058] In a specific embodiment, the present invention provides a pharmaceutical composition, comprising a first component and a second component, and the first component and the second component are stored separately, wherein the first component comprises 50-60% by weight of diolein, 4-15% by weight of soybean PC and 5-15% by weight of dimethylacetamide; the second component comprises 10-30% by weight of dimethylacetamide, 7-15% by weight of the compound represented by general formula I and methanesulfonic acid, and optionally further comprises maleic acid;

[0059] Alternatively, the first component comprises 50-60 wt% of dioleyl glycerol, 4-15 wt% of soybean PC, 20-35 wt% of dimethylacetamide and methanesulfonic acid, and optionally further comprises maleic acid; the second component comprises 7-15 wt% of the compound represented by general formula I;

[0060] When n1 is 1, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 1.2-2.2:1, and the weight content of maleic acid is 0-0.01%; when n1 is 2, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 0.9-1.2:1, and the weight content of maleic acid is 0-0.01%. Preferably, the compound represented by the general formula I is nalbuphine butyrate.

[0061] In another specific embodiment, the present invention provides a pharmaceutical composition comprising:

[0062] 7 to 15% by weight of the compound of formula I; preferably, the compound of formula I is nalbuphine butyrate;

[0063] 20 to 35% by weight of dimethylacetamide;

[0064] 50-60% by weight of diolein;

[0065] 4 to 15% by weight of soybean PC; and methanesulfonic acid, optionally also including maleic acid;

[0066] Wherein, when n1 is 1, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 1.2-2.2:1, and the weight content of maleic acid is 0-0.01%;

[0067] When n1 is 2, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 0.9-1.2:1, and the weight content of maleic acid is 0-0.01%.

[0068] In another specific embodiment, the present invention provides a pharmaceutical composition comprising:

[0069] 6-8% by weight of nalbuphine butyrate;

[0070] 25-30% by weight of dimethylacetamide;

[0071] 55-60% by weight of diolein;

[0072] 5-6 wt% soybean PC; and methanesulfonic acid, optionally also including maleic acid;

[0073] The molar ratio of nalbuphine butyrate to methanesulfonic acid is 2-2.2:1, and the weight content of maleic acid is 0-0.01%.

[0074] In another specific embodiment, the present invention provides a pharmaceutical composition comprising a first component and a second component,

[0075] The first component comprises 55-60% by weight of dioleyl glycerol, 5-6% by weight of soybean PC, and 5-11% by weight of dimethylacetamide; the second component comprises 19-25% by weight of dimethylacetamide, 6-8% by weight of nalbuphine butyrate, and methanesulfonic acid; wherein the molar ratio of nalbuphine butyrate to methanesulfonic acid is 2-2.2:1;

[0076] Further preferably, the first component and the second component are stored separately, preferably separately in vials.

[0077] In a preferred embodiment, the pharmaceutical composition of the present invention comprises a first component and a second component, the first component is stored in a first container, and the second component is stored in a second container; or the first component and the second component are respectively loaded into different compartments of a dual-compartment dispensing device for storage.

[0078] In one embodiment of the present invention, the first component is stored in a first container, and the second component is stored in a second container, and the first container and the second container are each independently selected from a vial, an ampoule or a prefilled syringe, and the prefilled syringe is a single-chamber, and preferably the prefilled syringe is a prefilled Luer lock syringe; for example, the first component and the second component are respectively stored in two independent vials; or the first component and the second component are respectively stored in two independent ampules; or one of the first component and the second component is stored in a vial, and the other component is stored in an ampoule; or the first component and the second component are respectively stored in two independent prefilled syringes, and the prefilled syringe is a single-chamber, and preferably the prefilled syringe is a prefilled Luer lock syringe.

[0079] In one embodiment of the present invention, the pharmaceutical composition comprising the first component and the second component described in the present invention can also be stored in a double-chamber prefilled syringe, wherein the double-chamber prefilled syringe comprises a front chamber and a rear chamber, and the first component is stored in the front chamber and the second component is stored in the rear chamber, or the first component is stored in the rear chamber and the second component is stored in the front chamber; preferably, the second component is stored in the front chamber and the first component is stored in the rear chamber.

[0080] The pharmaceutical composition comprising the first component and the second component of the present invention is a lyophilized powder injection, and is more preferably in the form of a final "ready-to-use medicine", also known as a "single dose" form, or a "unit preparation". Before use of the pharmaceutical composition, the first component and the second component are mixed, and the mixing method is not limited, and the mixing can be performed by any method known in the art. For example, when the first component and the second component are stored in the first container and the second container respectively, the first component can be sucked into the container containing the second component by a syringe, or all the liquid medicine can be sucked from the container (such as a vial) where the second component is located, transferred to the container (such as a vial) where the first component is located, shaken, visually observe that the liquid medicine becomes a homogeneous liquid medicine, remove bubbles in the liquid medicine, and suck all the liquid medicine with a syringe (such as an 18G needle), and replace the syringe needle. The first component and the second component are respectively stored in two independent prefilled syringes, such as prefilled Luer lock syringes, and the method of mixing the two components is also commonly used in the art, such as connecting the syringes containing the first component and the second component through a connector, such as screwing the two syringe Luer lock connectors onto the threads at both ends of the connector, and then slowly pushing the mixed solution back and forth in the two syringes until it is evenly mixed. The Luer lock syringes described above are currently commercial products that can be used, such as Luer lock syringes, Prefilled Luer Lock Polymer Syringes, HypakSCF from BD Healthcare TM PRTC glass prefilled syringe, Hylok TM Pre-filled systems, etc.

[0081] The dual-chamber prefilled syringe described in the present invention is a dual-chamber type syringe that also serves as a container. In such a dual-chamber prefilled syringe, a front plug is usually inserted into the front end side of the outer barrel, a rear plug is inserted into the rear end side of the outer barrel, and a middle plug is inserted into the central part of the outer barrel, so that the interior of the outer barrel is divided into a front and rear double chamber. The present invention does not limit the specific structure of this type of dual-chamber prefilled syringe, and the dual-chamber prefilled syringes that meet the pharmaceutical standards known in the art are applicable to the present invention. For example, Japanese Patent Publication No. 8-112333 and CN103228308A disclose similar dual-chamber type syringes that also serve as containers, which are incorporated into the present invention by reference.

[0082] The pharmaceutical composition with a specific auxiliary material ratio provided by the present invention has a fast onset of action, and unexpectedly, also has a slow release effect, and the auxiliary materials have good compatibility. Therefore, the pharmaceutical composition provided by the present invention can take effect quickly in the early stage after administration, and the drug can be slowly and continuously released for a long time in the later stage, and has a sustained analgesic effect. In addition, the pharmaceutical composition provided by the present invention also has the advantages of good compatibility of raw materials and auxiliary materials, high stability of the pharmaceutical composition, and less degradation of impurities.

[0083] Application

[0084] The pharmaceutical composition provided by the present invention is preferably administered parenterally. Administration will be performed by injection, such as any method by which the preparation is passed through the skin, subcutaneous or muscle by a needle, catheter or needleless syringe. In a preferred embodiment of the present invention, the pharmaceutical composition is stored in a final dosage unit, and the first component and the second component are mixed into a homogeneous liquid before use and delivered to a mammal (preferably a human) by a needle, preferably the parenteral administration is by subcutaneous (sc) or intramuscular (im) injection. The pharmaceutical composition of the present invention is also suitable for intracavitary administration, or by deeply buried in the subcutaneous to form a reservoir preparation. The inventors observed through experiments that after the pharmaceutical composition provided by the present invention is administered, the initial stage can take effect quickly, and then the active ingredient is released in a sustained release, and the analgesic effect is continuously exerted. Since the pharmaceutical composition of the present invention can form a gel reservoir at the injection site after being administered in vivo, the release time is allowed to be extended. The longer stable release period meets the needs of patient comfort and compliance, and the rapid onset after administration can be convenient for immediate administration before surgery, without the need for administration 1 day or even longer in advance.

[0085] The unit injection volume of the pharmaceutical composition provided by the present invention is preferably no more than 3 mL / each administration, more preferably no more than 2.5 mL / each administration, or no more than 2 mL / each administration, or no more than 1.8 mL / each administration, or no more than 1.5 mL / each administration or no more than 1 mL / each administration, etc. The pharmaceutical composition provided by the present invention comprising the first component and the second component is preferably a unit preparation for final administration, that is, a standard dose injection, the unit preparation contains at least 50 to 200 mg of the compound shown in the general formula I, preferably 100 to 200 mg, such as 100 mg, 120 mg, 150 mg, 180 mg or 200 mg, etc., preferably the unit preparation contains 120 to 150 mg of the compound shown in the general formula I, especially 150 mg; further preferably, the volume of the unit preparation of the pharmaceutical composition is about 3 mL / tube, or about 2 mL / tube, or about 1.9 mL / tube, or about 1.8 mL / tube, or about 1.5 mL / tube, or about 1 mL / tube, or about 0.5 mL / tube and any value therebetween.

[0086] Further preferably, the total volume of the first component and the second component of the pharmaceutical composition after mixing is 0.5-3 ml, such as 0.5 ml-1.0 ml, 0.5 ml-1.5 ml, 1.0 ml-1.5 ml, 1-2 ml, 1.5-2.0 ml, 1.8-2.0 ml, 2.0 ml-3.0 ml, about 0.5 ml, about 1.0 ml, about 1.5 ml, about 1.8 ml, or about 2.0 ml, etc.; more preferably 0.5 ml-1.5 ml, wherein the content of the compound represented by the general formula I is about 50 mg, or about 100 mg, or about 150 mg, or about 180 mg, or about 200 mg, etc. The "unit preparation" described in the present invention has the conventional meaning in the art, and refers to the smallest dosing unit or the smallest payment unit or the smallest packaging unit that can be split in the drug. For injections, the unit preparation is a dose of one.

[0087] On the other hand, pharmaceutical composition provided by the invention can be applied by disposable drug delivery device (optionally, also comprising device assembly).Such device will usually contain a single dose prepared for application, and is usually aseptically packaged, so that the pharmaceutical composition is stored in the device until administration.Disposable drug delivery device suitable for the present invention for example includes cartridges, ampoules, and particularly syringes, with integral needles or with needles (such as Luer (luer)) joints suitable for the dual chamber prefilled syringes adopted.Similar devices include needle-free syringes, multiple use or single use syringes and dual chamber prefilled syringe combinations, cartridges, or vials, or vials, or ampoules and syringes and / or injection needles and accessories thereof.

[0088] Specifically, the disposable drug delivery device may include two independent containers, and the size and shape of the two independent containers are not limited, as long as they can meet the sterility and regulatory requirements and usage requirements for the quality of pharmaceutical excipients and packaging materials. For example, the size of the container can be determined according to the volume of the first component and the second component in the pharmaceutical composition. According to the preferred dosage and volume of the aforementioned pharmaceutical composition of the present invention, the size of the container is preferably 0.5 to 5 ml, for example, about 0.5 ml, about 1 ml, about 1.5 ml, about 2 ml, about 2.5 ml, 3 ml, about 3.5 ml, about 4 ml or 5 ml, etc.

[0089] In a preferred embodiment of the present invention, the container is a vial, such as a vial and / or an ampoule, or the container is a prefilled syringe, the prefilled syringe is a single-chamber syringe, and preferably the prefilled syringe is a prefilled Luer lock syringe. The first component and the second component in the pharmaceutical composition of the present invention are respectively placed in two vials, such as vials and / or ampoules, that is, the first component can be stored in one vial and the second component can be stored in another vial or ampoule, or the first component can be stored in one ampoule and the second component can be stored in another ampoule or vial; the drug delivery device also includes a syringe, a syringe and a syringe syringe, and optionally also includes an injection needle, such as an 18G needle and / or a 23G needle. The devices included in the drug delivery device should be able to meet the requirements of at least one-time injection administration. For example, when the pharmaceutical composition is administered, it is necessary to use a syringe to transfer one component to another component and mix them evenly, and then administer it to an individual through a syringe. In a preferred embodiment, before administration, the first component is transferred to the container where the second component is located and mixed, or the second component is transferred to the container where the first component is located and mixed, and then administered to an individual through a syringe.

[0090] In a specific embodiment, for example, the pharmaceutical composition includes a first component and a second component, each of which is stored in a 2 ml vial. Those skilled in the art can adjust the method of use of the pharmaceutical composition of the present invention according to the needle-passing results, the convenience of clinical use, and the patient's acceptability, as well as the difficulty of absorbing and injecting each component. For example, use a 2 ml 18G syringe to absorb all the liquid medicine from the first component, transfer it to the vial (such as a vial) where the second component is located, shake for 1 min to 3 min, visually observe that the liquid medicine becomes a homogeneous liquid medicine, let it stand for about 5 min to eliminate the bubbles in the liquid medicine, use a 2 ml 18G syringe to absorb all the liquid medicine, replace the syringe needle with a 23G needle, and inject it into the patient.

[0091] In another embodiment, the disposable drug delivery device comprises a double-chamber prefilled syringe, wherein the first component and the second component of the pharmaceutical composition of the present invention are respectively placed in two different chambers of the double-chamber prefilled syringe, preferably, the second component is located in the front chamber of the double-chamber prefilled syringe, and the first component is located in the rear chamber. Optionally, the drug delivery device also has standard accessories suitable for disposable injection using a double-chamber syringe.

[0092] The dual-chamber prefilled syringe described in the present invention is consistent with the common understanding of those skilled in the art, such as the dual-chamber syringe prefilled for Abilify Maintena. For this type of dual-chamber prefilled syringe, there are already commercial products in the art that meet clinical use. In addition, any similar dual-chamber prefilled syringe that has been disclosed before the date of this application is suitable for the present invention, such as the dual-compartment product for aseptic mixing of substances disclosed in CN102482023A.

[0093] In another embodiment, the disposable drug delivery device may also use a prefilled syringe, which is a single-chamber syringe. Preferably, the prefilled syringe is a prefilled Luer lock syringe. The first component and the second component are respectively prefilled in the prefilled syringe, such as a prefilled Luer lock syringe. The drug delivery device should also include a connector that matches the Luer lock thread of the prefilled Luer lock syringe. Both ends of the connector have threads, and a prefilled Luer lock syringe containing the first component and a prefilled Luer lock syringe containing the second component can be connected through the connector, and then the first component and the second component can be evenly mixed in the two syringes. In addition, it also includes a needle and other accessories used in conjunction with the prefilled Luer lock syringe, so that the drug delivery device can at least meet the needs of disposable injection.

[0094] Therapeutic Uses

[0095] Another aspect of the present invention provides use of the pharmaceutical composition in preparing a drug for treating pain.

[0096] The present invention also provides a method for treating pain, comprising administering the pharmaceutical composition of the present invention to a subject in need thereof (eg, a mammalian subject, such as a human).

[0097] The pain of the present invention is selected from surgical pain or long-term chronic pain. The surgical operation includes but is not limited to common types of general surgery, such as hernia surgery, hemorrhoid surgery, abdominal surgery, plastic surgery, orthopedic surgery, otolaryngology surgery, etc.; the long-term chronic pain includes but is not limited to cancer pain, chronic back pain and chronic joint pain, etc.

[0098] Unless otherwise indicated, all percentages herein are by weight.The preformulation may consist essentially of these components only, and in one aspect consists entirely of these components.

[0099] Preparation method of pharmaceutical composition:

[0100] The present invention provides a method for preparing the pharmaceutical composition, the method comprising:

[0101] Method S1: adding the compound of formula I and an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then adding acylglycerol, and finally adding phosphatidylcholine, and dissolving them to obtain the product; or,

[0102] Method S2: first add an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then add acylglycerol and phosphatidylcholine in sequence, stirring and dissolving, and finally add the compound represented by general formula I, stirring and dissolving to obtain the product; or,

[0103] Method S3: adding diacylglycerol in a prescribed ratio to an oxygen-containing organic solvent, and then adding phosphatidylcholine, stirring and dissolving, as a first component;

[0104] Add the organic acid in the prescribed ratio to the remaining amount of the oxygen-containing organic solvent and stir to mix, then add the compound represented by the general formula I and dissolve and mix to form the second component. Alternatively,

[0105] Method S4: adding an organic acid in a prescribed ratio to an oxygen-containing organic solvent and stirring to mix well, then adding acylglycerol and phosphatidylcholine and stirring to dissolve, as a first component;

[0106] The compound represented by the general formula I in the prescribed proportion is used as the second component.

[0107] In some embodiments of the present invention, the preparation method further comprises filtering and sterilizing the prepared composition by passing it through a 0.22 μm sterile filtration membrane.

[0108] In a specific embodiment, the method for preparing the pharmaceutical composition comprises the following steps:

[0109] Dissolve the compound of formula I, methanesulfonic acid and optionally maleic acid in dimethylacetamide (or NMP) in a prescribed ratio, then add dioleylglycerol and stir, and finally add soybean PC and dissolve to obtain; or,

[0110] According to the prescription ratio, methanesulfonic acid and optional maleic acid are first dissolved in dimethylacetamide (or NMP), then diolein is added and stirred, then soybean PC is added and stirred to dissolve, and finally the compound represented by general formula I is added and stirred to dissolve.

[0111] Preferably, in the above method, when phosphatidylcholine is added for dissolution, the mixture is first heated to a temperature not exceeding 45° C., preferably to 40° C., which can significantly accelerate the dissolution rate.

[0112] In another specific embodiment, the method for preparing the pharmaceutical composition comprises the following steps:

[0113] Add GDO in the prescribed proportion to part of DMAC or NMP, then add soybean lecithin, stir and dissolve, as the first component;

[0114] Add methanesulfonic acid in the prescribed ratio to the remaining amount of DMAC or NMP and stir to mix, then add the compound of formula I and dissolve and mix to form the second component; or,

[0115] Add methanesulfonic acid in the prescribed ratio to DMAC or NMP and stir to mix, then add GDO and soybean lecithin and stir to dissolve as the first component;

[0116] The compound represented by the general formula I in the prescribed proportion is used as the second component.

[0117] In a specific embodiment, the method further includes storing the first component and the second component separately and independently, for example, the first component and the second component are stored separately from each other in different container devices (such as vials, such as vials, ampoules, etc., or prefilled syringes such as prefilled Luer lock glass syringes); or the first component and the second component are respectively loaded into different compartments of a dual-compartment dispensing device (dual-chamber prefilled syringe) for storage, etc., and the different containers and the dual-compartment dispensing device are as described in the context of the present invention.

[0118] In some embodiments of the present invention, the preparation method of the present invention further comprises filtering and sterilizing the prepared first component and / or second component by passing through a 0.22 μm sterile filtration membrane.

[0119] Compounds of general formula I and preparation methods thereof

[0120] In another aspect of the present invention, a method for preparing a compound of formula I is provided, the method comprising reacting nalbuphine with a carboxyl-containing compound RCOOH in a suitable organic solvent (such as dichloromethane, DMF, DMSO, dioxane, ethyl acetate, NMP or DMAC, etc.) to obtain an alkyl acid ester compound of nalbuphine, wherein R is a straight chain or branched chain alkyl. It is further preferred that RCOOH is propionic acid, butyric acid, n-pentanoic acid, heptanoic acid, decanoic acid and some saturated fatty acids CH 3 (CH 2 ) m1 COOH, wherein m1 is an integer from 1 to 15, such as lauric acid, palmitic acid, etc.

[0121] The method further comprises reacting nalbuphine with a dicarboxylic acid HOOC-(CH 2 ) m2 -COOH reaction to obtain a nalbuphine alkyl acid monoester compound, wherein m2 is an integer of 1 to 15, and preferably, the dicarboxylic acid is selected from adipic acid, sebacic acid, undecanedioic acid, dodecanedioic acid or tetradecanedioic acid.

[0122] The method further comprises reacting nalbuphine with a dicarboxylic acid, a dicarboxylic acid anhydride or a carboxylic acid derivative containing two carbonyl chlorides to obtain a nalbuphine diester compound, preferably, the dicarboxylic acid is selected from HOOC-(CH2) m2 -COOH, wherein m2 is an integer of 1 to 15, more preferably, the dicarboxylic acid is selected from adipic acid, sebacic acid, undecanedioic acid, dodecanedioic acid or tetradecanedioic acid; the dicarboxylic anhydride is selected from adipic anhydride, dodecanedioic anhydride or tetradecanedioic anhydride; the carboxylic acid derivative containing two carbonyl chlorides is selected from ClOC-(CH2) m2 -COCl, wherein m2 is an integer from 1 to 15, more preferably adipoyl chloride, ClOC-(CH2) 8 -COCl, ClOC-(CH2) 10 -COCl, or ClOC-(CH2) 12 -COCl, etc. CN1190438C discloses a method for preparing nalbuphine diester, and the disclosure thereof is fully incorporated into the present invention by reference.

[0123] In another aspect of the present invention, a novel compound is provided, wherein the compound has the following structure:

[0124]

[0125] In the present invention, the parameter range selection includes the endpoint values, for example, 5-20% by weight includes the endpoint values ​​"5%" and "20%"; the ratio range 1.2-2.2:1 includes "1.2:1" and "2.2:1". In particular, when referring to a given numerical value, the terms "about" and "around" indicate that the specified amount is a primary embodiment, but the actual amount should not be significantly different from the specified amount, as judged by a person skilled in the art, unless the context prohibits, otherwise this will generally be ±10%, ±5%, ±3%, ±2%, ±1%, ±0.5% or ±0.05% of the specified value, etc.

[0126] “Optional,” “optional,” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0127] The term "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other aspects. It should be understood that the term "comprising" can include a closed meaning, that is, "consisting of...".

[0128] Unless otherwise indicated, all % are specified by weight throughout this article. In addition, unless otherwise indicated, the weight percentages of diacylglycerols (such as GDO), phosphatidylcholine (such as soybean PC), oxygen-containing organic solvents (such as NMP or DMAC), organic acids (such as maleic acid, methanesulfonic acid, etc.) and compounds shown in general formula I indicated in the context of the present invention are relative to the total weight of (a), (b), (c), (d) and (e).

[0129] In the present invention, "soybean PC" refers to soybean phosphatidylcholine, wherein PC is the abbreviation of phosphatidylcholine.

[0130] When a pharmaceutical composition is referred to herein as "consisting essentially of certain ingredients," the specified ingredient provides the essential properties of the pharmaceutical composition, such as when the specified ingredient constitutes at least 95%, preferably at least 98%, of the pharmaceutical composition.

[0131] Unless the context prohibits, when the active ingredient is indicated herein as a compound of formula I, the compound of formula I in the form of any pharmaceutically acceptable salt is also disclosed. Suitable pharmaceutically acceptable salts are well known in the art, such as halides (especially chlorides), acetates, pamoates and the like. Specific embodiments

[0132] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0133] Preparation Example 1: Preparation method of nalbuphine sebacic acid monoester

[0134]

[0135] Dichloromethane (100 ml), compound G01 (5.0 g), and sebacic acid (2.85 g) were added to a 250 ml reaction bottle, and DMAP (0.86 g) and EDCI (2.97 g) were added under stirring. The reaction was carried out at room temperature and monitored by TLC. After completion of the reaction, sodium chloride solution was added and stirred for separation. The organic phase was concentrated to dryness to obtain white solid G02.

[0136] Add acetonitrile (12.5 ml), acetic acid (12.5 ml), G02 (2.5 g) to a 100 ml reaction bottle, and add Me4NBH(OAc) under stirring. 3(2.44 g), react at room temperature, concentrate after the reaction, add ethyl acetate and saturated sodium bicarbonate, separate the liquids, concentrate the organic phase to dryness, and dry to obtain nalbuphine sebacic acid monoester, with a yield of 80.5%.

[0137] Preparation Example 2: Preparation method of nalbuphine dodecanedioic acid diester

[0138]

[0139] Add dichloromethane (50 ml), SO1 (5.0 g) and triethylamine (2.14 g) into a 250 ml reaction bottle, add dodecanedioyl dichloride (2.07 g) while stirring at room temperature, react at room temperature until complete, add saturated sodium bicarbonate, separate the layers, extract with dichloromethane, combine the organic phases, concentrate under reduced pressure, and dry to obtain white solid SO2.

[0140] Add acetonitrile (10 ml), acetic acid (10 ml), SO2 (2.0 g) into a 100 ml reaction bottle, and add Me 4 NBH(OAc) 3 (2.32 g), stirred at room temperature, concentrated until no liquid was distilled off after the reaction was completed, added ethyl acetate and saturated sodium carbonate for separation, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, concentrated and dried to obtain nalbuphine dodecanedioic acid diester, with a yield of 75%.

[0141] Preparation Example 3: Preparation method of nalbuphine tetradecanedioic acid diester

[0142]

[0143] Dichloromethane (20 ml), ethyl acetate (20 ml), and e01 (5.0 g) were added to a 100 ml reaction bottle. Tetradecanoic acid (1.81 g), DMAP (0.86 g), and EDCI (2.84 g) were added under stirring. The mixture was stirred at room temperature. After the reaction was completed, the mixture was extracted with concentrated ethyl acetate, the solvent was evaporated, and the compound e02 was dried. The yield was 76.2%.

[0144] To a 100 ml reaction bottle, acetonitrile (15 ml), acetic acid (15 ml), e02 (3.0 g), and Me4NBH(OAc)3 (4.2 g) were added and stirred at room temperature. After the reaction was completed, the mixture was concentrated, and ethyl acetate and aqueous sodium carbonate solution were added. The layers were separated, and the organic phase was concentrated and dried to obtain the target compound in a yield of 80.73%.

[0145] Preparation Example 4: Preparation method of nalbuphine adipate diester

[0146]

[0147] DCM (40 ml), j01 (5.0 g, 14.1 mmol), and triethylamine (2.14 g) were added to a 250 ml reaction bottle, and the temperature was lowered to 10±5°C. Adipoyl chloride (1.42 g) was added dropwise. After the temperature was raised to room temperature, water was added, stirred, and the liquids were separated. The organic phase was concentrated until no obvious liquid dripped out, ethanol was added, heated to dissolve, cooled to room temperature, and filtered to obtain compound j02 with a yield of 71%.

[0148] A 100 ml reaction bottle was added with acetonitrile (10 ml), acetic acid (10 ml), intermediate j02 (2.0 g), Me4NBH (OAc) 3 (2.56 g), react at room temperature, concentrate after the reaction is completed, add ethyl acetate and sodium carbonate to separate the liquids, concentrate the organic phase, and dry to obtain the target compound with a yield of 87%.

[0149] Preparation Example 5: Preparation method of nalbuphine butyrate

[0150]

[0151] In a 100 ml reaction bottle, dichloromethane (12 ml), ethyl acetate (12 ml), d01 (3.0 g), butyric acid (0.82 g), DMAP (0.52 g l), and EDCI (1.78 g) were added. The reaction was heated to 30±3°C and the reaction was completed. 12 ml of water was added and the dichloromethane was removed by concentration. Ethyl acetate was added and the liquids were separated. The organic phase was concentrated to dryness to obtain the intermediate d02 in a yield of 55%.

[0152] To a 100 ml reaction bottle, acetonitrile (10 ml), acetic acid (10 ml), intermediate d02 (1.98 g), and Me4NBH(OAc)3 (3.06 g, 11.6 mmol) were added. The mixture was stirred at room temperature until the reaction was completed. The mixture was concentrated at 55°C until no liquid was evaporated. Ethyl acetate and sodium carbonate were added. The liquids were separated. The organic phase was concentrated and dried to obtain the target product in a yield of 65.3%.

[0153] DMAC mentioned in the following examples refers to N,N-dimethylacetamide, NMP refers to N,N-dimethylpyrrolidone; GDO refers to diolein, and soybean PC refers to soybean phosphatidylcholine. The nalbuphine sebacate monoester (purity: 96.20%), senabuphine (purity: 99.40%), nalbuphine butyrate (purity: 98.95%), and nalbuphine adipate (purity: 94.7%) used in the examples are all prepared by the method described in the present invention. Nalbuphine (source: Sanofi); soybean PC (source: Shenyang Tianfeng Biopharmaceutical Co., Ltd.); diolein (source: Croda, UK); Natache Solution (source: Shuntian Pharmaceutical Biotechnology Co., Ltd.).

[0154] Example 1: Prescription and preparation of pharmaceutical composition

[0155] The pharmaceutical compositions of the corresponding compounds were prepared according to the prescription composition in Table 1.1.

[0156] Preparation method:

[0157] The compounds (senabuphine, nalbuphine sebacic acid monoester, nalbuphine dodecanedioic acid diester, nalbuphine tetradecanedioic acid diester, nalbuphine butyrate and nalbuphine adipate diester) in the prescription ratio of Table 1.1 and methanesulfonic acid were stirred and dissolved in DMAC, and then GDO was added and stirred well, and finally soybean PC was added, and the mixture was heated to 40°C to dissolve to prepare the corresponding pharmaceutical composition.

[0158] Table 1.1 Prescription of drug composition

[0159]

[0160]

[0161] The obtained pharmaceutical compositions of batches 01a to 04a, 06a to 07a were subjected to dissolution testing.

[0162] Dissolution method:

[0163] Dissolution apparatus: Agilent 708-DS; High performance liquid chromatography: Shimadzu LC-20AD liquid chromatograph; Basket method; Dissolution medium: pH 7.0 + 0.25% SDS, medium volume 900ml, rotation speed 50rpm; Medium temperature 37°C; Sampling volume 1.5ml; Sampling method: 1.5ml rehydration; Sample amount per basket: 150mg; Sampling time points: 15min, 30min, 1h, 2h, 4h, 5h. HPLC detection was performed, and its dissolution curve was calculated. The experimental results show that the pharmaceutical composition provided in Table 1.1 has a faster onset of action than senabuphine, and the analgesic duration is similar or longer.

[0164] Example 2: Prescription and preparation of pharmaceutical composition

[0165] The pharmaceutical composition of the compound represented by the general formula I was prepared according to the prescription composition in Table 2.1.

[0166] The first component: add the prescribed amount of GDO to an oxygen-containing organic solvent (such as N,N-dimethylacetamide or N,N-dimethylpyrrolidone), then add soybean lecithin (soybean PC), stir to dissolve, and heat to 40°C to speed up the dissolution;

[0167] The second component: adding a prescribed amount of an acid (such as methanesulfonic acid) to an oxygen-containing organic solvent (such as N,N-dimethylacetamide or N,N-dimethylpyrrolidone) and stirring to mix well, and then adding the compound represented by the general formula I to dissolve and mix well;

[0168] The first component and the second component in each prepared composition were stored separately in 2 ml vials.

[0169] Table 2.1 Prescription of pharmaceutical composition

[0170]

[0171]

[0172] Where “ / ” means none.

[0173] The first component and the second component of the samples of the above 6 prescriptions were placed in a 25℃±2℃ / RH60%±5% stability test box for 1 month and in a 2~8℃ refrigerator for 1 month, and then the first component and the second component were mixed and tested for properties and purity. The purity was tested by HPLC. The test results showed that the purity of the above samples did not change after being placed at 25℃ and 2~8℃ for 1 month, indicating that the samples had good stability.

[0174] Example 3: Stability study of pharmaceutical composition

[0175] Table 3.1 Ratio of raw material and auxiliary material prescription

[0176]

[0177] Note: API: refers to the active ingredient of the drug, corresponding to the headings of senabuphine, nalbuphine sebacate monoester, nalbuphine dodecanedioate diester, nalbuphine tetradecanedioate diester, nalbuphine butyrate, and nalbuphine adipate diester.

[0178] Add the methanesulfonic acid in the amount prescribed in Table 3.1 to DMAC or NMP and stir to mix, then add API (senabuphine, nalbuphine sebacic acid monoester, nalbuphine dodecanedioic acid diester, nalbuphine tetradecanedioic acid diester, nalbuphine butyrate, nalbuphine adipate diester) to dissolve and mix to obtain the corresponding pharmaceutical compositions.

[0179] The stability study was conducted on the pharmaceutical compositions of the above batch numbers 01c-04c, 06c-07c. The samples from the six batches were placed under accelerated test conditions (40°C ± 2°C / RH 75% ± 5% stability test chamber). The maximum single impurity and total impurity contents were tested on the 0th day, 15th day and 30th day, respectively. The test results are shown in Table 3.2.

[0180] Table 3.2: Increase in the amount of related substances in each batch of pharmaceutical composition relative to day 0

[0181]

[0182] Note: / indicates not tested. Since the test results of batch 03c pharmaceutical composition on the 15th day showed a large increase in impurities, indicating that the compatibility of the raw materials and excipients of the pharmaceutical composition was poor, no further testing was performed on the 30th day.

[0183] From the test results in Table 3.2, it can be seen that the pharmaceutical compositions of nalbuphine butyrate and nalbuphine sebacate have higher stability, indicating that the compatibility of pharmaceutical excipients is better. The maximum single impurity and total impurity content of the pharmaceutical composition of nalbuphine dodecanedioic acid diester increased significantly under the same conditions, indicating that the stability of the pharmaceutical composition is poor. The impurity content of the pharmaceutical composition of nalbuphine butyrate did not change on the 15th day compared with the 0th day, and the maximum single impurity content did not change on the 30th day of the accelerated test, and the total impurity content did not increase significantly, indicating that the formulations of the nalbuphine sebacate pharmaceutical composition and the nalbuphine butyrate pharmaceutical composition provided by the present invention have good stability.

[0184] Test Example 1: Analgesic Effect Study

[0185] Take male SPF SD rats weighing 180-220 kg and breed them for 4 days. Perform initial screening of rats and eliminate sensitive animals.

[0186] Surgical modeling: Except for the blank control group, all other groups underwent surgical operations, 7% chloral hydrate was used as an anesthetic, and the volume of oral administration was 6.3 ml / kg. The surface of the surgical site on the sole of the rat was disinfected with iodine tincture, and a 1 cm longitudinal incision was made from 0.5 cm forward from the edge of the heel, including the skin, fascia and plantar muscle, and the skin was sutured with two stitches, and pressure was applied to stop bleeding and clean the wound.

[0187] Postoperative grouping: The basal values ​​were tested again 24 hours after surgery and averaged into groups to keep the basal values ​​of each group as consistent as possible: blank group, model group, nalbuphine butyrate pharmaceutical composition (batch 06a) 100 mpk group, 75 mpk group, and nalbuphine butyrate 100 mpk group and 75 mpk group; the unit mpk refers to milligrams per kilogram (Milligrams Per Kilograms).

[0188] Administration: On the second day after modeling, different concentrations of solutions were prepared for administration according to different doses in each group. The blank group, model group, and nalbuphine butyrate drug composition were administered subcutaneously on the back, and nalbuphine was administered into the right thigh muscle. The solvents for the blank group and model group were normal saline.

[0189] Mechanical pain withdrawal threshold (MWT) test: The software automatically records the mechanical pain withdrawal threshold (MWT) at 30 minutes, 4 hours, and 28 hours after modeling, and the Mann-whitney test is used for statistical analysis. The calculation formula for the MWT improvement rate (%) is:

[0190] MWT improvement rate (%) = (MWT value of drug administration group - MWT value of model group) / MWT value of model group × 100

[0191] The test results show that the nalbuphine butyrate pharmaceutical composition 100 mpk showed significant analgesic effect at 30 min, 4 h and 28 h, with a faster onset time and more significant analgesic effect.

[0192] Based on the above ideal embodiments of this application, the relevant staff can make various changes and modifications without departing from the technical concept of this application through the above description. The technical scope of this application is not limited to the content in the specification, and its technical scope must be determined according to the scope of the claims.

Claims

1. A pharmaceutical composition comprising a compound of formula I, characterized in that: The pharmaceutical composition comprises (a) diacylglycerol, (b) phosphatidylcholine, (c) an oxygen-containing organic solvent, (d) at least one organic acid and (e) a compound represented by general formula I; Wherein, the compound represented by the general formula I has the following structure: Where n1 is 1 or 2; When n1 is 1, R1 is selected from: a straight chain or branched chain alkyl group containing 1 to 14 carbon atoms, an alkylene carboxyl group containing 1 to 15 carbon atoms, or H; When n1 is 2, R1 is selected from: -(CH2) n2 -, where n2 is 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14 or 15; Preferably, the straight or branched alkyl group containing 1 to 14 carbon atoms is selected from C 1~3 A straight or branched alkyl group, C 4~9 A straight or branched chain alkyl group, or C 10~14 A straight chain or branched alkyl group; Preferably, the alkylene carboxyl group containing 1 to 15 carbon atoms is selected from a straight chain or branched chain alkylene carboxyl group containing 1 to 15 carbon atoms, more preferably: -(CH2) n3 -COOH, wherein n3 is an integer from 1 to 15; Further preferably, the compound represented by the general formula I, wherein R1 is selected from methyl, ethyl, n-propyl, tert-butyl, n-hexyl, or -(CH2) 13 -CH3, n1 is selected from 1; Further preferably, the compound represented by the general formula I, wherein the R1 is selected from -(CH2) n3 -COOH, wherein n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15; preferably n3 is 4, 6, 8, 10, or 12; Further preferably, the compound represented by the general formula I, wherein the R1 is selected from -(CH2) n2 -, where n2 is 4, 6, 10, 12, 13, 14 or 15; Further preferably, the compound represented by the general formula I is selected from any compound in the following Table A: Table A 2. The pharmaceutical composition according to claim 1, characterized in that Mode A: (a) diacylglycerol, (b) phosphatidylcholine and part of (c) oxygen-containing organic solvent are the first component of the pharmaceutical composition, and the remaining (c) oxygen-containing organic solvent, (d) at least one organic acid and (e) the compound represented by general formula I are the second component of the pharmaceutical composition; or Mode B: (a) diacylglycerol, (b) phosphatidylcholine, (c) oxygen-containing organic solvent and (d) at least one acid are the first component of the pharmaceutical composition, and (e) the compound represented by general formula I is the second component of the pharmaceutical composition; and the first component and the second component are stored separately; Preferably, in method A, the weight ratio of the oxygen-containing organic solvent in the first component to that in the second component is (0.2-2):1; It is further preferred that the first component is stored in a first container and the second component is stored in a second container; or the first component and the second component are respectively stored in different compartments of a dual-compartment dispensing device; Further preferably, the first component is stored in a first container, and the second component is stored in a second container, wherein the first container and the second container are independently selected from a vial, an ampoule or a prefilled syringe, and the prefilled syringe is preferably a prefilled Luer lock syringe; or, the pharmaceutical composition is stored in a double-chamber prefilled syringe, the double-chamber prefilled syringe comprises a front chamber and a rear chamber, the first component is stored in the front chamber, and the second component is stored in the rear chamber, or the first component is stored in the rear chamber, and the second component is stored in the front chamber; Further preferably, before use of the pharmaceutical composition, the first component and the second component are mixed evenly.

3. The pharmaceutical composition according to any one of claims 1 to 2, characterized in that The content of the compound represented by the general formula I is 5 to 20% by weight, preferably 7 to 15% by weight; The content of diacylglycerol is 40 to 65% by weight, preferably 50 to 60% by weight; The content of phosphatidylcholine is 4 to 15% by weight, preferably 4 to 10% by weight; The molar ratio of the compound represented by the general formula I to the organic acid is 0.9 to 3:1; The content of the oxygen-containing organic solvent is 15 to 50% by weight, preferably 20 to 35% by weight; The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e); Further preferably, when n1 is 1, the molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1; When n1 is 2, the molar ratio of the compound represented by the general formula I to the organic acid is 0.9-1.2:

1.

4. The pharmaceutical composition according to any one of claims 1 to 2, characterized in that The content of the compound represented by the general formula I is 5 to 10% by weight; The content of diacylglycerol is 50-60% by weight; The content of phosphatidylcholine is 4 to 10% by weight; The content of the oxygen-containing organic solvent is 20 to 35% by weight; When n1 is 1, the molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1; When n1 is 2, the molar ratio of the compound represented by the general formula I to the organic acid is 0.9 to 1.2:1; The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e).

5. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that (a) the diacylglycerol is diolein; (b) the phosphatidylcholine is selected from at least one of egg PC, heart PC, brain PC, liver PC, egg yolk PC or soybean PC, preferably at least one of egg PC, egg yolk PC or soybean PC, more preferably soybean PC; (c) the oxygen-containing organic solvent is selected from at least one of amides, C1-C3 alcohols or benzyl alcohol, and the amides are selected from at least one of N-methylpyrrolidone, dimethylformamide, 2-pyrrolidone and dimethylacetamide, preferably N-methylpyrrolidone and / or dimethylacetamide. (d) The organic acid is at least one of methanesulfonic acid, maleic acid, p-toluenesulfonic acid, acetic acid, fumaric acid and citric acid, preferably at least one of methanesulfonic acid or maleic acid.

6. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition comprises a first component and a second component, and the first component and the second component are stored separately, wherein the first component comprises 50-60 weight % of dioleyl glycerol, 4-15 weight % of soybean PC and 5-20 weight % of dimethylacetamide; the second component comprises 10-30 weight % of dimethylacetamide, 7-15 weight % of the compound represented by general formula I, and methanesulfonic acid, and optionally further comprises maleic acid; Alternatively, the first component comprises 50-60 wt% of dioleyl glycerol, 4-15 wt% of soybean PC, 20-35 wt% of dimethylacetamide, and methanesulfonic acid, and optionally further comprises maleic acid; the second component comprises 7-15 wt% of the compound represented by general formula I; When n1 is 1, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 1.2-2.2:1; when n1 is 2, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 0.9-1.2:1, and the content of maleic acid is 0-0.01%.

7. The pharmaceutical composition according to any one of claims 1 to 2, characterized in that The pharmaceutical composition comprises: 7 to 15% by weight of the compound represented by the general formula I; 20 to 35% by weight of dimethylacetamide; 50-60% by weight of diolein; 4-15% by weight of soybean PC; and methanesulfonic acid, optionally also maleic acid; Wherein, when n1 is 1, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 1.2-2.2:1, and the weight content of maleic acid is 0-0.01%; When n1 is 2, the molar ratio of the compound represented by the general formula I to methanesulfonic acid is 0.9-1.2:1, and the weight content of maleic acid is 0-0.01%.

8. The pharmaceutical composition according to any one of claims 1 to 7, characterized in that The unit dosage of the pharmaceutical composition contains 50 to 200 mg, preferably 100 to 150 mg of the compound of formula I.

9. A compound, characterized in that It has the following structure:

10. Use of the pharmaceutical composition according to any one of claims 1 to 8, or the compound according to claim 9 in the preparation of a medicament for treating pain; Preferably, the pain is selected from surgical pain or long-term chronic pain; further preferably, the pain is selected from pain caused by hernia surgery, hemorrhoid surgery, abdominal surgery, plastic surgery, orthopedic surgery, otolaryngology surgery, cancer pain, chronic back pain or chronic joint pain.

11. A method for preparing the pharmaceutical composition according to any one of claims 1 to 8, comprising the following steps: Method S1: adding the compound of formula I and an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then adding acylglycerol, and finally adding phosphatidylcholine, and dissolving them to obtain the product; or, Method S2: first add an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then add acylglycerol and phosphatidylcholine in sequence, stirring and dissolving, and finally add the compound represented by general formula I, stirring and dissolving to obtain the product; or, Method S3: adding diacylglycerol in a prescribed ratio to a portion of an oxygen-containing organic solvent, and then adding phosphatidylcholine, stirring and dissolving, as a first component; Adding an organic acid in a prescribed ratio to the remaining amount of an oxygen-containing organic solvent and stirring to mix well, then adding the compound represented by the general formula I and dissolving and mixing well to form the second component; or, Method S4: adding an organic acid in a prescribed ratio to an oxygen-containing organic solvent and stirring to mix well, then adding acylglycerol and phosphatidylcholine and stirring to dissolve, as a first component; The compound of formula I in the prescribed proportion is used as the second component; Preferably, in the above method, when phosphatidylcholine is added to dissolve, the mixture is first heated to a temperature not exceeding 45°C.

Citation Information

Patent Citations

  • Packaged products, inserts and compartments for aseptic mixing of substances, along with methods for use therewith

    CN102482023A

  • Two-chambered container-cum-syringe and syringe-filled aripiprazole

    CN103228308A

  • Nabufulin polybasic ester derivative and its production method

    CN1190438C

  • Method for packing freeze drying agent of prefilled syringe of type to dissolve when needed

    JP1996112333A

  • Pharmaceutical composition containing dinalbuphine sebacate

    WO2023020608A1

Cited By

  • Nalbuphine hydrochloride injection and preparation method thereof

    CN119385942A